658 filings
8-K
DRRX
Durect Corp
30 Apr 24
Other Events
2:30pm
424B5
DRRX
Durect Corp
28 Mar 24
Prospectus supplement for primary offering
5:26pm
10-K
2023 FY
DRRX
Durect Corp
Annual report
28 Mar 24
4:52pm
8-K
DRRX
Durect Corp
27 Mar 24
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:15pm
8-K
DRRX
Durect Corp
22 Mar 24
Other Events
4:05pm
8-K
xtutwdj5 erb1y0qn
4 Mar 24
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZETĀ® Product Line in U.S. and Canada
11:37am
8-K
fwp5q 0y56qly1qd0
22 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
1z5 fev0ws3dxurka
13 Nov 23
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
4:15pm
8-K
g7hz y9egv4g2u1h8
7 Nov 23
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
4:10pm
8-K
45d1orj
7 Sep 23
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial
9:02am
S-8
5i32x80
10 Aug 23
Registration of securities for employees
4:21pm
8-K
534huu8
9 Aug 23
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
4:23pm
8-K
pbdf7
21 Jul 23
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
5:13pm
424B5
6kf94ckm
21 Jul 23
Prospectus supplement for primary offering
10:38am
8-K
yynbgq7t75n
22 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
4v9eh0ns9m9
7 Jun 23
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
9:00am
8-K
wnjempytbn5 zusr
16 May 23
Regulation FD Disclosure
12:08pm